KD Pharma Group’s Post

𝐌𝐢𝐜𝐫𝐨𝐜𝐚𝐫𝐫𝐢𝐞𝐫𝐬 𝐌𝐚𝐫𝐤𝐞𝐭 𝐖𝐨𝐫𝐭𝐡 𝐏𝐫𝐨𝐣𝐞𝐜𝐭𝐞𝐝 𝐭𝐨 𝐑𝐞𝐚𝐜𝐡 $𝟑.𝟑 𝐛𝐢𝐥𝐥𝐢𝐨𝐧 𝐛𝐲 𝟐𝟎𝟐𝟖 𝐃𝐨𝐰𝐧𝐥𝐨𝐚𝐝 𝐭𝐡𝐞 𝐏𝐃𝐅 𝐁𝐫𝐨𝐜𝐡𝐮𝐫𝐞 𝐚𝐭 https://lnkd.in/gaQtEvbz The global microcarriers market in terms of revenue was estimated to be worth $2.0 billion in 2023 and is poised to reach $3.3 billion by 2028, growing at a CAGR of 10.0% from 2023 to 2028. 𝐊𝐞𝐲 𝐏𝐥𝐚𝐲𝐞𝐫𝐬: Thermo Fisher Scientific. Sartorius AG Danaher Corporation Merck KGaA, Darmstadt, Germany Corning Pharmaceutical Technologies FUJIFILM Holdings America Corporation BD Eppendorf SE Lonza Getinge ChemoMetec Esco Lifesciences Group. Entegris bbi-biotech GmbH STEMCELL Technologies STEMCELL Technologies China Stobbe Group - CerCell - PerfuseCell - Cronus-PCS Distek, Inc. BIONET G&G Technologies, Inc. Tantti Laboratory Inc. Kuhner shaker AG PBS Biotech REPROCELL Meissner Smart MCs Pty Ltd #microcarriersmarket #microcarriers

PeptiSystems can't wait to attend #EPS2024 in Florence in a few days! If you want to reduce the PMI of your peptide synthesis, come to booth #19 to discuss with Lukasz and Florence how flow SPPS with recirculation revolutionizes the sustainability of peptide manufacturing If you stay for the workshop, come and listen about the approach selected by PeptiSystems AB and Corden Pharma - A Full-Service CDMO to embrace innovation and sustainability in peptide synthesis. #EPS2024, #flowsynthesis, #SPPS, #flowthrough, #peptidesynthesis

Dr. Dimitrios Zarkadas, PhD, PMP of Merck & Co. will present “Process Development and Robust Control of Physical Attributes of an Amorphous Drug Substance”, at the 5th Pharma Crystallization Summit (#PCS2024) in Session 2 - Particle Engineering to Address Formulation Challenge. You can read the abstract and speaker abstract at https://lnkd.in/eevSRP5W Please register now to secure your seat, at https://lnkd.in/eubD65m3 We look forward to another exciting PCS with stimulating and fruitful sharing and discussions on the pressing topics in support of today’s new drug development. #PharmaCrystallizationSummit #DebottleneckingDrugDevelopment #ChallengingCrystallization #ParticleEngineering #ComputationTool

Portage, Michigan and Irvine, California, Jan. 06, 2025 (GLOBE NEWSWIRE) --Stryker (NYSE: SYK), a global leader in medical technologies, announced today a definitive agreement to acquire all of the issued and outstanding shares of common stock of Inari Medical, Inc. (NASDAQ: NARI) for $80 per share in cash, representing a total fully diluted equity value of approximately $4.9 billion. Inari, which was founded in 2011, will bring a leading peripheral vascular position in the fast-g... https://bit.ly/3PL68vz #pharma #biotech #lifesciences #clinicalresearch #news #pharmiweb

We’re excited to be partnering with NJ Bio, Inc. to accelerate #antibody drug conjugate (ADC) discovery and development. Learn how our strategic alliance combines Charles River’s end-to-end ADC discovery services with NJ Bio’s bioconjugation and manufacturing capabilities: https://okt.to/naHXOJ

#SuvenPharma acquires a 56% controlling #stake in US-based Contract Research and Development Manufacturing Organisation NJ Bio Inc, specialising in antibody-drug conjugates (ADC). https://lnkd.in/gMUmAXPy

🌟 Explore the world of lipid manufacturing and process chemistry at #DDFSummit! Join Joel Richard, PhD, HDR, Chief Development Officer at Enterome, for an insightful session on "Controlling Stability of Biologics During Product Lifecyle in Pre-filled Syringes: A Focus on Aggregates and Leachable" 🧪🔬

𝐉𝐨𝐢𝐧 us in Washington for 𝐂𝐈𝐂𝐎𝐍 where innovators and investors connect. Intavis Peptide Services specializes in comprehensive peptide solutions, from pre-clinical to clinical trial stages. If peptides are your focus, seize this opportunity to discuss collaborations and 𝐚𝐜𝐜𝐞𝐥𝐞𝐫𝐚𝐭𝐞 𝐲𝐨𝐮𝐫 𝐝𝐫𝐮𝐠 𝐝𝐞𝐯𝐞𝐥𝐨𝐩𝐦𝐞𝐧𝐭 𝐰𝐢𝐭𝐡 𝐨𝐮𝐫 𝐮𝐧𝐩𝐚𝐫𝐚𝐥𝐥𝐞𝐥𝐞𝐝 𝐬𝐮𝐩𝐩𝐨𝐫𝐭. Check the link in the comment and Start Your Project with Us Today. #peptides #biotech #cdmo #drugdevelopment #CICON

Are you interested in better (more uniform) siliconization process for primary container systems for combination products? Please see our recent publication "Centrifuge Siliconization of Primary Container Systems" in Journal of Pharmaceutical Sciences. Kudos to my colleagues Brian Wong, Kaitlin Wang, PhD, Kavin Kowsari, Yongchao Su, William Forrest, Ph.D. and Jeff Givand. The team takes great pride in leveraging best engineering and science to drive combination product innovation and robustness. https://lnkd.in/ezaigsKm

Serán is pleased to announce the addition of an MG2 Planeta capsule filling machine to support development and mid-to large-scale GMP production. This investment expands our small scale MG2 development encapsulation capabilities and reflects our commitment to providing advanced technologies and expanded capabilities to support our customers' growing manufacturing demands, including late-stage and commercial-scale production.  The MG2 Planeta capsule filling machine delivers exceptional performance, combining cutting-edge technology with the quality and reliability our customers expect. With the ability to fill up to 3,000 - 50,000 - with the potential for 100,000 - capsules per hour, it features the integrated multiNETT system for 100% in-process net fill weight control, ensuring precise dosing for every capsule. This platform will enable a variety of filling options, including powders, beads, tablets, minitablets, and other modalities, including mixed modalities. At Serán, we are dedicated to equipping our development and GMP manufacturing operations with industry-leading technology to meet the evolving needs of our customers. #CDMO #drugdelivery #MG2 #MGAmerica #OSD